Swiss National Bank Boosts Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

Swiss National Bank boosted its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 23.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 347,800 shares of the company’s stock after buying an additional 65,800 shares during the quarter. Swiss National Bank owned 0.16% of Hims & Hers Health worth $8,410,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Quest Partners LLC raised its stake in Hims & Hers Health by 22.6% during the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after acquiring an additional 807 shares in the last quarter. Stonekeep Investments LLC grew its position in Hims & Hers Health by 5.5% during the 4th quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock worth $410,000 after purchasing an additional 882 shares during the last quarter. Principal Securities Inc. boosted its holdings in shares of Hims & Hers Health by 48.2% in the fourth quarter. Principal Securities Inc. now owns 3,079 shares of the company’s stock valued at $74,000 after acquiring an additional 1,002 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Hims & Hers Health by 1.9% in the fourth quarter. Victory Capital Management Inc. now owns 52,579 shares of the company’s stock valued at $1,271,000 after acquiring an additional 1,002 shares in the last quarter. Finally, Cadent Capital Advisors LLC boosted its holdings in shares of Hims & Hers Health by 1.5% in the fourth quarter. Cadent Capital Advisors LLC now owns 72,160 shares of the company’s stock valued at $1,745,000 after acquiring an additional 1,060 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Stock Performance

Hims & Hers Health stock opened at $34.77 on Friday. The company has a market cap of $7.72 billion, a P/E ratio of 79.02 and a beta of 1.37. The firm’s 50-day moving average is $39.21 and its 200-day moving average is $28.69. Hims & Hers Health, Inc. has a 1 year low of $11.20 and a 1 year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.02. The firm had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. As a group, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently commented on HIMS shares. Leerink Partners raised their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research note on Tuesday, February 25th. Needham & Company LLC lifted their target price on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a research report on Tuesday, February 25th. Piper Sandler boosted their price objective on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a research report on Tuesday, February 25th. BTIG Research started coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 target price for the company. Finally, Citigroup reissued a “sell” rating and issued a $27.00 price objective on shares of Hims & Hers Health in a research report on Thursday, March 6th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $37.31.

Insider Buying and Selling at Hims & Hers Health

In other news, insider Soleil Boughton sold 4,152 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total value of $251,984.88. Following the transaction, the insider now owns 157,345 shares of the company’s stock, valued at $9,549,268.05. The trade was a 2.57 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Michael Chi sold 7,259 shares of Hims & Hers Health stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $24.07, for a total transaction of $174,724.13. Following the completion of the transaction, the insider now directly owns 193,601 shares in the company, valued at approximately $4,659,976.07. This trade represents a 3.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,015,547 shares of company stock valued at $36,146,450. Company insiders own 17.71% of the company’s stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.